Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Product images are for illustration purposes only
Dysregulation of brain reward systems in eating disorders: neurochemical information from animal models of binge eating, bulimia nervosa, and anorexia nervosa
The ability to change with fluctuating dopamine levels makes the DRD3 receptor critical in dopamine-related functions and cognition.[ref] DRD4 receptor: This dopamine receptor is found at lower levels than DRD1 through DRD3
Using them together isn't necessarily bad, but it can overwhelm sensitive skin